Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-02-20
2008-08-26
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S105000, C544S263000, C544S281000, C544S284000, C544S235000, C544S353000, C544S333000, C546S117000, C546S119000, C546S120000, C546S121000, C546S122000, C546S112000, C546S250000, C514S259310, C514S266200, C514S248000, C514S249000, C514S256000, C514S300000, C514S303000, C514S299000, C514S332000, C514S341000
Reexamination Certificate
active
07417041
ABSTRACT:
Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-β signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
REFERENCES:
patent: 3119742 (1964-01-01), Heimlich et al.
patent: 3492397 (1970-01-01), Peters et al.
patent: 3538214 (1970-11-01), Polli et al.
patent: 4060598 (1977-11-01), Groppenbācher et al.
patent: 4173626 (1979-11-01), Demski et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 6664395 (2003-12-01), Letavic et al.
patent: 6696464 (2004-02-01), McClure et al.
patent: 2003/0092749 (2003-05-01), Dombroski et al.
patent: 2004/0106608 (2004-06-01), Munchhof et al.
patent: 2004/0110797 (2004-06-01), Munchhof et al.
patent: 2004/0110798 (2004-06-01), Munchhof et al.
patent: 2004/0116473 (2004-06-01), Munchhof et al.
patent: 2004/0116474 (2004-06-01), Munchhof et al.
patent: 0231622 (1987-08-01), None
patent: 0257897 (1988-03-01), None
patent: 0306300 (1989-03-01), None
patent: 0364204 (1990-04-01), None
patent: WO9630347 (1996-10-01), None
patent: WO9852937 (1998-11-01), None
patent: WO9852941 (1998-11-01), None
patent: WO0031063 (2000-06-01), None
patent: WO0061576 (2000-10-01), None
patent: WO0162756 (2001-08-01), None
patent: WO0172737 (2001-10-01), None
patent: WO0216359 (2002-02-01), None
patent: WO0240468 (2002-05-01), None
patent: WO0240476 (2002-05-01), None
patent: WO02055077 (2002-07-01), None
patent: WO02062787 (2002-08-01), None
patent: WO02062794 (2002-08-01), None
patent: WO02066462 (2002-08-01), None
patent: WO02072576 (2002-09-01), None
patent: WO0300682 (2003-01-01), None
patent: WO03087304 (2003-10-01), None
patent: WO2004013135 (2004-02-01), None
patent: WO2004013138 (2004-02-01), None
patent: WO2004021989 (2004-03-01), None
Strutz (Expert Opin. Investig. Drugs, 2001, 10(11), 1989-2001).
Klose, W., et al., “Synthese von Pyridylphenyl-imidazo[2,1-b]thiazolen”,J. Heterocyclic Chem., vol. 22, pp. 669-671 (1985).
Callahan J., et al., Indentification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5),J. Med. Chem., vol. 45, pp. 999-1001 (2002). Published on Web Jan. 30, 2002.
Database Chemabs Online, Chemical Abstracts Service, CAPLUS Database Accession No. 1989:94933.
Laping, et al., “Inhibition of Transforming Growth Factor (TGF)-β1-Induced Extracellular Matrix with a Novel Inhibitor of the TGF-βType I Receptor Kinase Activity: SB-431542”, Mol. Pharmacol., 62:58-64, 2002.
Moran, et al., “Synthesis of (Pyridinyl)-1,2,4-triazolo[4,3-α]pyridines” J. Heterocycl. Chem., 23:1071-1077, 1986.
Singh, et al., “Successful Shap-Based Virtual Screening: The Discovery of a Potent Inhibitor of the Type I TGFβ Receptor Kinase (TβRI)”, Bioorganic & Medicinal Chemistry Letters, 13, pp. 4355-4359 (2003).
Blumberg Laura C.
Munchhof Michael J.
Shavnya Andrei
Coleman Brenda
Engelmann John H.
Lee Christine S.
Moore Susanna
Pfizer Inc.
LandOfFree
Imidazopyrimidines as transforming growth factor (TGF)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazopyrimidines as transforming growth factor (TGF)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazopyrimidines as transforming growth factor (TGF)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3993020